North America Virus-like Particles Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. North America Virus-like Particles Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. North America Virus-like Particles Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. North America Virus-like Particles Market Regional Analysis

6.2 North America Virus-like Particles Market Revenue 2019-2028 (US$ Million)

6.3 North America Virus-like Particles Market Forecast Analysis

7. North America Virus-like Particles Market Analysis – by Product Type

7.1 Hepatitis

7.1.1 Overview
7.1.2 Hepatitis: North America Virus-like Particles Market – Revenue and Forecast, 2019-2028 (US$ Million)

7.2 Cancer/HPV

7.2.1 Overview
7.2.2 Cancer/HPV: North America Virus-like Particles Market – Revenue and Forecast, 2019-2028 (US$ Million)

7.3 Gaucher disease

7.3.1 Overview
7.3.2 Gaucher disease: North America Virus-like Particles Market – Revenue and Forecast, 2019-2028 (US$ Million)

8. North America Virus-like Particles Market Analysis – by Source

8.1 Yeast

8.1.1 Overview
8.1.2 Yeast: North America Virus-like Particles Market – Revenue and Forecast, 2019-2028 (US$ Million)

8.2 Insect Cell

8.2.1 Overview
8.2.2 Insect Cell: North America Virus-like Particles Market – Revenue and Forecast, 2019-2028 (US$ Million)

8.3 Plant

8.3.1 Overview
8.3.2 Plant: North America Virus-like Particles Market – Revenue and Forecast, 2019-2028 (US$ Million)

9. North America Virus-like Particles Market Analysis – by Application

9.1 Vaccines and Therapeutics

9.1.1 Overview
9.1.2 Vaccines and Therapeutics : North America Virus-like Particles Market – Revenue and Forecast, 2019-2028 (US$ Million)

10. North America Virus-like Particles Market – North America Analysis

10.1 Overview

10.2 North America

10.2.1 North America Virus-like Particles Market Breakdown, by Key Country, 2022 and 2028 (%)
10.2.1.1 North America Virus-like Particles Market – Revenue and Forecast Analysis – by Country
10.2.1.1 US: North America Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)

10.2.1.1.1 US: North America Virus-like Particles Market Breakdown, by Product Type
10.2.1.1.2 US: North America Virus-like Particles Market Breakdown, by Source
10.2.1.1.3 US: North America Virus-like Particles Market Breakdown, by Application

10.2.1.2 Canada: North America Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)

10.2.1.2.1 Canada: North America Virus-like Particles Market Breakdown, by Product Type
10.2.1.2.2 Canada: North America Virus-like Particles Market Breakdown, by Source
10.2.1.2.3 Canada: North America Virus-like Particles Market Breakdown, by Application

10.2.1.3 Mexico : North America Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)

10.2.1.3.1 Mexico : North America Virus-like Particles Market Breakdown, by Product Type
10.2.1.3.2 Mexico : North America Virus-like Particles Market Breakdown, by Source
10.2.1.3.3 Mexico : North America Virus-like Particles Market Breakdown, by Application

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Industry Landscape

12.1 Overview

12.2 Market Initiative

12.3 Partnerships and Collaborations

12.4 Other Developments

13. Company Profiles

13.1 Merck & Co., Inc.

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 GlaxoSmithKline plc.

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Pfizer Inc.

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Sanofi

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Serum Institute of India Pvt. Ltd.

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 BHARAT BIOTECH

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 LG Chem

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 VBI Vaccines Inc.

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Dynavax Technologies

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

14. Appendix

14.1 About Business Market Insights

14.2 List of Abbreviations

North America Virus-like Particles Market

Analysis By Product Type (Hepatitis, Cancer/HPV, and Gaucher disease), Source (Yeast, Insect Cell, Plant, and Others), and Application (Vaccines and Therapeutics)